Navigation Links
Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH
Date:11/10/2008

Responses Significantly Correlated to Overall Survival Summary: Three ofatumumab Abstracts Have Been Accepted for Presentation at

the ASH Meeting December 6-9, 2008

COPENHAGEN, November 10 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that three ofatumumab (HuMax-CD20(R)) abstracts have been accepted for presentation at the 50th American Society of Hematology Annual Meeting and Exposition (ASH) December 6-9, 2008. Updated interim efficacy data from the pivotal study evaluating ofatumumab to treat two groups of chronic lymphocytic leukemia (CLL) patients with an unmet medical need will be presented in an oral session. Headline interim data from the study was announced in July 2008.

In addition, two abstracts on pre-clinical ofatumumab data have been accepted for presentation at poster sessions. All three ofatumumab abstracts are available on the ASH website at http://www.hematology.org.

ASH Sessions

Oral Presentation December 8 at 11:45AM PST - Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial.

Poster I-682 - Complement (C) Activation Followed by Penetration of the Membrane Attack Complex (MAC) on B Cells Opsonized with CD20 Mabs Allows for Calcium Influx Which Induces Streamers.

Poster I-683 - Binding of Submaximal C1q to B Cells Opsonized with Anti-CD20 Mabs Ofatumumab (OFA) or Rituximab (RTX) Promotes Complement Dependent Cytotoxicity (CDC), and Considerably Higher Levels of CDC Are Induced by OFA Than by RTX.

Ofatumumab is an investigational, new generation, human monoclonal antibody that targets a distinct membrane proximal, small loop epitope (specific binding site) of the CD20 molecule on t
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Genmab Announces Results for the First Nine Months of 2008
2. Genmab Reaches Milestone in Ofatumumab Collaboration
3. Genmab Reaches Fifth Milestone in Ofatumumab Collaboration
4. Genmab A/S - Changes Board/Management/Auditors
5. Genmab Initiates Zalutumumab Combination Study in Colorectal Cancer
6. Genmab Announces 2008 First Quarter Results
7. Passing of Genmab A/S Annual General Meeting
8. Genmab A/S - Notice to Convene Annual General Meeting
9. Genmabs 2007 Annual Report
10. Genmab Announces Year End 2007 Financial Results
11. Genmab and PDL BioPharma Close Sale of Antibody Manufacturing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , March 3, 2015  RegeneRx Biopharmaceuticals, Inc. ... in the scientific journal, Expert Opinion on Biological ... colleague, Dr. Zhenggang Zhang , at the Henry ... reported that Thymosin beta 4 (TB4) has the capacity ... 24 hours or more post-injury, leading to neurological recovery ...
(Date:3/3/2015)... Corner, New Jersey (PRWEB) March 03, 2015 ... NJ, has announced today that it has acquired ... Terms of the transaction were not announced. ... consulting services to the energy sector including oil ... alternative energy, and fossil and nuclear power sectors. ...
(Date:3/3/2015)... Research and Markets ( http://www.researchandmarkets.com/research/gxqhg9/gene_therapy ... new report "Gene Therapy - Technologies, Markets ... Gene therapy technologies are described in ... therapy with genetically modified vectors. Gene therapy is ... routes of administration as well as targeted gene ...
(Date:3/3/2015)... MN , March 3, 2015 /PRNewswire/ - BioAmber ... company producing sustainable chemicals, today announced it has initiated ... plant located in Sarnia, Ontario , ... to take approximately five months, with the facility being ... construction to be completed in two months and it ...
Breaking Biology Technology:Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 3BioAmber Begins Commissioning of Sarnia Commercial Plant 2BioAmber Begins Commissioning of Sarnia Commercial Plant 3
... Biological Sciences Research Council (BBSRC) have shown that past ... complex decisions based on uncertain or confusing information. They ... in our brains so that we can quickly categorise ... carry out appropriate actions. The research is published today ...
... charged method at Reproductive Science Center of the San ... In response to growing numbers of couples who want ... Reproductive Science Center of the San Francisco Bay Area ... alternative gender-selection technique with fewer moral and ethical dilemmas. ...
... May 13 SpectraScience, Inc. (OTC Bulletin Board: ... today announced that it has established a distribution ... Krainer Medtechnik, a Vienna-based firm specializing in the ... devices.Michel Vaudry, SpectraScience,s VP Sales and Marketing, commented, ...
Cached Biology Technology:Brain research shows past experience is invaluable for complex decision making 2Gender-Selection Technique Embraced for Hopeful Parents 2SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Germany & Austria 2SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Germany & Austria 3
(Date:2/5/2015)... , Jan. 30, 2015  It is gratifying ... power and potential for genomic science as a means ... disease prevention and treatment.  I was honored to participate ... government-funded precision medicine program. Since the ... science of genomics—from the first sequenced genome of a ...
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source ... launch of its new website design. "When we ... infancy", says Peter O,Neill , founder and CEO of ... industry needs involvement from the key players on a very ...
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... will be crucial to buffer the negative effects of climate ... a new landmark study. The findings of the multi-author ... based on samples of ecosystems in every continent except Antarctica. ... diverse an ecosystem is, the more ecological functions it performs. ...
... published online in the FASEB Journal ( http://www.fasebj.org ... the intestines may be used to predict a person,s likelihood ... may help reduce heart attack risk. This discovery may lead ... prevent and treat heart attacks. In addition, this research suggests ...
... their foraging due to changes in wind fields in the ... in intensity and moved to the south, the flight speed ... a consequence, breeding success has improved and birds have gained ... an international research team published in the latest issue of ...
Cached Biology News:Diverse ecosystems are crucial climate change buffer 2The microbiome and disease: Gut bacteria influence the severity of heart attacks in rats 2Largest bird alters its foraging due to climate change 2Largest bird alters its foraging due to climate change 3
... (PTO) oligonucleotides: PTOs are internucleotide ... phosphate backbone is replaced by a sulphur ... nuclease degradation. PTOs are available as ... phosphothioates Oligonucleotides with thio-caps ...
Improve inventory management with stainless steel red cell canisters; ensure product safety with CO2 or LN2 backup systems. A complete solution for your blood banking needs....
... S and 135 S steam sterilizers with their ... the advantages of a double-walled device - low ... and drying by built-in jacket heater - with ... The chamber is free of furnishings and feed ...
... RNase H- Reverse Transcriptase (RT) is an ... RT. It is a DNA polymerase that ... RNA DNA or an RNA:DNA hybrid. This ... of point mutations rather than a deletion ...
Biology Products: